BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 21430343)

  • 1. Translational research on advanced therapies.
    Belardelli F; Rizza P; Moretti F; Carella C; Galli MC; Migliaccio G
    Ann Ist Super Sanita; 2011; 47(1):72-8. PubMed ID: 21430343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of the Istituto Superiore di Sanità as the competent authority for Phase I trials in the translation of advanced therapies.
    Popoli P; Cometa MF; Fabi F; Meneguz A
    Ann Ist Super Sanita; 2011; 47(1):79-82. PubMed ID: 21430344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulatory structures for gene therapy medicinal products in the European Union.
    Klug B; Celis P; Carr M; Reinhardt J
    Methods Enzymol; 2012; 507():337-54. PubMed ID: 22365782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The NCI All Ireland Cancer Conference.
    Johnston PG; Daly PA; Liu E
    Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Education of laboratory technicians at graduate school contributes to development of advanced medical sciences and therapeutics].
    Maekawa T
    Rinsho Byori; 2004 May; 52(5):430-4. PubMed ID: 15206130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulatory enablers and regulatory challenges for the development of tissue-engineered products in the EU.
    Brévignon-Dodin L
    Biomed Mater Eng; 2010; 20(3):121-6. PubMed ID: 20930319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of advanced therapy medicinal products in Europe and the role of academia.
    Pearce KF; Hildebrandt M; Greinix H; Scheding S; Koehl U; Worel N; Apperley J; Edinger M; Hauser A; Mischak-Weissinger E; Dickinson AM; Lowdell MW
    Cytotherapy; 2014 Mar; 16(3):289-97. PubMed ID: 24113428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Good Manufacturing Practices (GMP) manufacturing of advanced therapy medicinal products: a novel tailored model for optimizing performance and estimating costs.
    Abou-El-Enein M; Römhild A; Kaiser D; Beier C; Bauer G; Volk HD; Reinke P
    Cytotherapy; 2013 Mar; 15(3):362-83. PubMed ID: 23579061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hurdles in clinical implementation of academic advanced therapy medicinal products: A national evaluation.
    de Wilde S; Veltrop-Duits L; Hoozemans-Strik M; Ras T; Blom-Veenman J; Guchelaar HJ; Zandvliet M; Meij P
    Cytotherapy; 2016 Jun; 18(6):797-805. PubMed ID: 27068764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. European Medicines Agency, CAT Secretariat & US Food and Drug Administration.
    Regen Med; 2011 Nov; 6(6 Suppl):90-6. PubMed ID: 21999268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Translational medicine policy issues in infectious disease.
    Fears R; van der Meer JW; ter Meulen V
    Sci Transl Med; 2010 Jan; 2(14):14cm2. PubMed ID: 20371464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of the blood service in cellular therapy.
    Rebulla P; Giordano R
    Biologicals; 2012 May; 40(3):218-21. PubMed ID: 22063066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products in Europe.
    Schuessler-Lenz M; Herberts C; Reischl I; Ruiz S; Celis P; Beuneu C; Kjeken R; Timón M
    Adv Exp Med Biol; 2023; 1430():1-21. PubMed ID: 37526839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory aspects for translating gene therapy research into the clinic.
    Laurencot CM; Ruppel S
    Methods Mol Biol; 2009; 542():397-421. PubMed ID: 19565915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The expanding role of blood and tissue establishments in the development of advanced therapy medicinal products.
    Horan A; Warreth S; Hervig T; Waters A
    Cytotherapy; 2024 May; 26(5):524-530. PubMed ID: 38441513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A comprehensive assessment of ATMP. Difficulties and approaches].
    Thanner M; Nagel E
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):843-8. PubMed ID: 21698538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospects of Advanced Therapy Medicinal Products-Based Therapies in Regenerative Dentistry: Current Status, Comparison with Global Trends in Medicine, and Future Perspectives.
    Bakopoulou A
    J Endod; 2020 Sep; 46(9S):S175-S188. PubMed ID: 32950189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current regulatory issues in cell and tissue therapy.
    Burger SR
    Cytotherapy; 2003; 5(4):289-98. PubMed ID: 12944234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. European regulatory tools for advanced therapy medicinal products.
    Flory E; Reinhardt J
    Transfus Med Hemother; 2013 Dec; 40(6):409-12. PubMed ID: 24474890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.